Rohit Bose

Rohit Bose, MD, PhD, is an Assistant Professor in the Department of Anatomy at the University of California, San Francisco (UCSF) School of Medicine. He is a physician-scientist and practicing medical oncologist specializing in prostate cancer, leading a research laboratory focused on tumor evolution and therapeutic resistance. His work integrates clinical practice with cutting-edge molecular and genomic research to improve patient outcomes.

Education:

• MD/PhD, Medicine & Molecular Genetics, University of Toronto, 2008
• Residency, Medical Research Track, Internal Medicine, Weill Cornell Medicine, 2010
• Fellowship, Medical Research Track, Medical Oncology, Memorial Sloan Kettering Cancer Center (MSKCC), 2014
• Fellowship, Advanced Oncology, MSKCC, 2016
• Instructor, Dept. of Medicine, Genitourinary Service, MSKCC, 2018

Dr. Bose's research centers on understanding how prostate tumors evolve during therapy, particularly in response to hormonal treatments. His lab has pioneered a novel immunocompetent platform for continuous tumor evolution screening, enabling the study of shifting tumor dependencies and the identification of strategies to maintain cells in therapy-sensitive states. His primary research interests include tumor evolution, prostate cancer genomics, transcription factor biology, high-throughput screening, and hormone-related cancers. His recent publications highlight work in cancer evolution, biomarker discovery for therapies like enfortumab vedotin and 177Lu-PSMA-617, and the use of digital tools to enhance patient decision-making in advanced prostate cancer.

Scientific Awards and Honors:

• NIH DP2 New Innovator Award, 2023
• Idea Development Award, Department of Defense, Prostate Cancer Program, 2023–2026
• Research Scholar Grant, American Cancer Society, 2022–2026
• Bakar Aging Research Institute Investigator Award, UCSF, 2021
• Young Investigator Award, Prostate Cancer Foundation, 2016–2019
• Dana Fellow in Biomedical Research, 2011–2013
• And numerous other national and institutional awards

Dr. Bose has been the Principal Investigator on multiple significant research grants, including NIH DP2, NIH K08, Department of Defense, and American Cancer Society funding, supporting his work on tumor evolution and therapy resistance. His publications in top journals such as Nature, Nature Genetics, and The Lancet Oncology reflect his leadership in prostate cancer research. He is actively involved in clinical and translational research, contributing to advancements in precision oncology and patient-centered care.